Pieris Pharmaceuticals Inc (PIRS)
16.26
+0.33
(+2.05%)
USD |
NASDAQ |
Nov 22, 10:32
Pieris Pharmaceuticals Net Income (Quarterly): -2.887M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -2.887M |
| June 30, 2024 | -3.59M |
| March 31, 2024 | -4.892M |
| December 31, 2023 | -4.584M |
| September 30, 2023 | -10.75M |
| June 30, 2023 | 3.976M |
| March 31, 2023 | -13.18M |
| December 31, 2022 | -8.102M |
| September 30, 2022 | -9.736M |
| June 30, 2022 | -10.34M |
| March 31, 2022 | -5.101M |
| December 31, 2021 | -9.532M |
| September 30, 2021 | -16.54M |
| June 30, 2021 | -15.50M |
| March 31, 2021 | -4.172M |
| December 31, 2020 | -14.40M |
| September 30, 2020 | -14.28M |
| June 30, 2020 | -4.95M |
| March 31, 2020 | -3.597M |
| December 31, 2019 | -0.771M |
| September 30, 2019 | -2.592M |
| June 30, 2019 | -11.76M |
| Date | Value |
|---|---|
| March 31, 2019 | -10.35M |
| December 31, 2018 | -11.68M |
| September 30, 2018 | -6.153M |
| June 30, 2018 | -0.203M |
| March 31, 2018 | -8.714M |
| December 31, 2017 | 7.491M |
| September 30, 2017 | -7.059M |
| June 30, 2017 | -10.08M |
| March 31, 2017 | -7.994M |
| December 31, 2016 | -6.558M |
| September 30, 2016 | -6.196M |
| June 30, 2016 | -5.883M |
| March 31, 2016 | -4.161M |
| December 31, 2015 | -2.902M |
| September 30, 2015 | -3.922M |
| June 30, 2015 | -3.53M |
| March 31, 2015 | -3.705M |
| September 30, 2014 | -0.0139M |
| June 30, 2014 | -0.0062M |
| March 31, 2014 | -0.0015M |
| December 31, 2013 | -0.0022M |
| September 30, 2013 | -0.0058M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-16.54M
Minimum
Sep 2021
3.976M
Maximum
Jun 2023
-7.646M
Average
-6.602M
Median
Net Income (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | -7.172M |
| NovaBay Pharmaceuticals Inc | -1.212M |
| Palatin Technologies Inc | -7.824M |
| iBio Inc | -3.989M |
| Theriva Biologics Inc | -7.726M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.135M |
| EPS Diluted (Quarterly) | -2.19 |
| Enterprise Value | 1.673M |
| Earnings Yield | -74.85% |
| Normalized Earnings Yield | -6.422 |